BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 29935688)

  • 1. Peritoneal Metastases from Malignant Mesothelioma.
    Li CY; Alexander HR
    Surg Oncol Clin N Am; 2018 Jul; 27(3):539-549. PubMed ID: 29935688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current Management and Future Opportunities for Peritoneal Metastases: Peritoneal Mesothelioma.
    Alexander HR; Li CY; Kennedy TJ
    Ann Surg Oncol; 2018 Aug; 25(8):2159-2164. PubMed ID: 29423664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiological predictors of complete cytoreduction in 59 patients with peritoneal mesothelioma treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy at a UK referral centre.
    Chandramohan A; Thrower A; Shah N; Mohamed F
    Br J Radiol; 2017 Nov; 90(1079):20170361. PubMed ID: 28830230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy.
    Le Roy F; Gelli M; Hollebecque A; Honoré C; Boige V; Dartigues P; Benhaim L; Malka D; Ducreux M; Elias D; Goéré D
    Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis.
    Helm JH; Miura JT; Glenn JA; Marcus RK; Larrieux G; Jayakrishnan TT; Donahue AE; Gamblin TC; Turaga KK; Johnston FM
    Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicystic and diffuse malignant peritoneal mesothelioma in children.
    Vermersch S; Arnaud A; Orbach D; Andre N; Berger C; Kepenekian V; Brigand C; Fresneau B; Poli-Merol ML; Habougit C; Varlet F; Scalabre A
    Pediatr Blood Cancer; 2020 Jun; 67(6):e28286. PubMed ID: 32277799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies.
    Polanco PM; Ding Y; Knox JM; Ramalingam L; Jones H; Hogg ME; Zureikat AH; Holtzman MP; Pingpank J; Ahrendt S; Zeh HJ; Bartlett DL; Choudry HA
    Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy.
    Li YC; Khashab T; Terhune J; Eckert RL; Hanna N; Burke A; Richard Alexander H
    Ann Surg Oncol; 2017 Aug; 24(8):2259-2265. PubMed ID: 28324285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial.
    de Boer NL; van Kooten JP; Burger JWA; Verhoef C; Aerts JGJV; Madsen EVE
    BMJ Open; 2019 May; 9(5):e026779. PubMed ID: 31092657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current trends in the management of malignant peritoneal mesothelioma.
    Miura JT; Johnston FM; Gamblin TC; Turaga KK
    Ann Surg Oncol; 2014 Nov; 21(12):3947-53. PubMed ID: 24841356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature.
    Stamou K; Tsamis D; Pallas N; Samanta E; Courcoutsakis N; Prassopoulos P; Tentes AA
    Int J Hyperthermia; 2015; 31(8):850-6. PubMed ID: 26382910
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current concepts in the evaluation and treatment of patients with diffuse malignant peritoneal mesothelioma.
    Turner K; Varghese S; Alexander HR
    J Natl Compr Canc Netw; 2012 Jan; 10(1):49-57. PubMed ID: 22223869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
    Kusamura S; Torres Mesa PA; Cabras A; Baratti D; Deraco M
    Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival.
    Verma V; Sleightholm RL; Rusthoven CG; Koshy M; Sher DJ; Grover S; Simone CB
    Ann Surg Oncol; 2018 Jul; 25(7):2018-2026. PubMed ID: 29721724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome.
    Ihemelandu C; Bijelic L; Sugarbaker PH
    Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preventing recurrence of diffuse malignant peritoneal mesothelioma.
    Leinwand JC; Chabot JA; Kluger MD
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):989-95. PubMed ID: 27486718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recurrence of Optimally Treated Malignant Peritoneal Mesothelioma with Cytoreduction and Heated Intraperitoneal Chemotherapy.
    Heller DR; Chiuzan C; Taub RN; Leinwand JC; Greene AM; Bates GE; Chabot JA; Kluger MD
    Ann Surg Oncol; 2017 Dec; 24(13):3818-3824. PubMed ID: 29027138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience.
    Wong J; Koch AL; Deneve JL; Fulp W; Tanvetyanon T; Dessureault S
    Ann Surg Oncol; 2014 May; 21(5):1480-6. PubMed ID: 24158467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oncolytic vaccinia virus as an adjuvant treatment to cytoreductive surgery for malignant peritoneal mesothelioma.
    Acuna SA; Ottolino-Perry K; Çako B; Tang N; Angarita FA; McCart JA
    Ann Surg Oncol; 2014 Jul; 21(7):2259-66. PubMed ID: 24719018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Malignant peritoneal mesothelioma. Our experienced with triple combined therapy: cytoreduction, intraperitoneal perioperative chemotherapy and hyperthermia].
    Gómez Portilla A; Cendoya I; Muriel J; Olabarria I; Guede N; Moraza N; Fernández E; Martínez de Lecea C; Magrach L; Martín E; Romero E; Aguado I; Valdovinos M; Larrabide I
    Cir Esp; 2007 Feb; 81(2):82-6. PubMed ID: 17306123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.